Literature DB >> 14643958

Assessment of morbidity in carcinoma of the cervix: a comparison of the LENT SOMA scales and the Franco-Italian glossary.

Susan E Davidson1, Meriel P Burns, Jacqueline A Routledge, Ric Swindell, Søren M Bentzen, Catharine M L West.   

Abstract

BACKGROUND AND
PURPOSE: To assess the correlation between the LENT (late effects on normal tissue) SOMA (subjective objective management analytic) system and the Franco-Italian glossary scores of late morbidity in cervical cancer patients treated with radiation, and to compare the ability of the scoring systems to detect differences between radiation treatment groups.
MATERIALS AND METHODS: The study was retrospective. Patients, invited to take part in the study, had radiotherapy for cervical cancer and had a minimum of 3 years follow-up with no evidence of recurrence. One hundred patients agreed to take part. LENT subjective data were obtained using a patient questionnaire approach in order to complete the scales as published. The LENT objective, management and Franco-Italian glossary scores were obtained by a physician. Correlations between scores and differences between treatment groups were examined using non-parametric tests.
RESULTS: The average LENT SOMA scores had a greater resolution than the maximum scores, and using the maximum score alone underestimated treatment morbidity. The Franco-Italian glossary scores correlated strongly with the LENT objective scores (rho=0.61, P<0.0005), and less strongly with the LENT subjective scores (rho=0.45, P<0.0005). Significant differences in morbidity between the radiation treatment groups were measured using both the LENT SOMA system and the Franco-Italian glossary.
CONCLUSIONS: The maximum and average LENT scores should be reported for each subsite. The LENT objective scores correlated well with the scores obtained using the established Franco-Italian glossary, but the LENT system provided additional information on subjective treatment effects. Both systems were able to measure significant differences in morbidity between radiation treatment groups. In conclusion, the LENT SOMA system is a valid and comprehensive approach for scoring the late normal tissue effects of radiotherapy.

Entities:  

Mesh:

Year:  2003        PMID: 14643958     DOI: 10.1016/j.radonc.2003.09.005

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  6 in total

1.  An observational trial to establish the effect of hyperbaric oxygen treatment on pelvic late radiation tissue injury due to radiotherapy.

Authors:  James Andren; Michael H Bennett
Journal:  Diving Hyperb Med       Date:  2020-09-30       Impact factor: 0.887

2.  Time course of late rectal- and urinary bladder side effects after MRI-guided adaptive brachytherapy for cervical cancer.

Authors:  P Georg; A Boni; A Ghabuous; G Goldner; M P Schmid; D Georg; R Pötter; W Dörr
Journal:  Strahlenther Onkol       Date:  2013-05-25       Impact factor: 3.621

3.  Substantial improvement in UK cervical cancer survival with chemoradiotherapy: results of a Royal College of Radiologists' audit.

Authors:  C L Vale; J F Tierney; S E Davidson; K J Drinkwater; P Symonds
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-07-01       Impact factor: 4.126

4.  A study of chronic pelvic pain after radiotherapy in survivors of locally advanced cervical cancer.

Authors:  Ingvild Vistad; Milada Cvancarova; Gunnar Balle Kristensen; Sophie Dorothea Fosså
Journal:  J Cancer Surviv       Date:  2011-01-23       Impact factor: 4.442

5.  Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer.

Authors:  H Jervoise N Andreyev; Susan E Davidson; Catherine Gillespie; William H Allum; Edwin Swarbrick
Journal:  Gut       Date:  2011-11-04       Impact factor: 23.059

6.  The impact of radiotherapy late effects on quality of life in gynaecological cancer patients.

Authors:  C L Barker; J A Routledge; D J J Farnell; R Swindell; S E Davidson
Journal:  Br J Cancer       Date:  2009-04-21       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.